Plus Therapeutics, Inc. (PSTV) - Wutah bathi EPS kuartalan
The absence of revenue during the testing phase and inflated laboratory costs limit the operating leverage of Plus Therapeutics, Inc. (PSTV), while supply chain disruptions and patent complexities heighten risks. The quarterly EPS change reflects profit dynamics, where 97.30 represents the current metric. The company's prospects are based on the implementation of Rhenium-186 for targeted irradiation of brain and breast tumors.
%20Wutah%20bathi%20resik%20saben%20saham%20taun-ka-taun%20sajrone%2012%20wulan%20pungkasan&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_PSTV_-_Plus-Therapeutics-Inc._-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "Wutah bathi EPS kuartalan Cytori Therapeutics (PSTV): kanggo periode 04.07.2022 - 03.08.2026 | 👁️GURU.Markets👁️")
Rincian analitis perusahaan Plus Therapeutics (PSTV)
Plus Therapeutics, Inc. (PSTV) specializes in developing innovative radiopharmaceuticals for targeted irradiation of neoplasms, monetizing its technology through insurance reimbursements at oncology centers. Analyzing the quarterly change in earnings per share allows for an assessment of this business model's efficiency and the company's ability to protect capital, preventing overpayment for the asset as EPS growth rates normalize.
